HK1148948A1 - 用於治療自身免疫疾病的跨膜激活劑及鈣調親環素配基相互作用因子 和抗- 試劑的組合 - Google Patents
用於治療自身免疫疾病的跨膜激活劑及鈣調親環素配基相互作用因子 和抗- 試劑的組合Info
- Publication number
- HK1148948A1 HK1148948A1 HK11103143.7A HK11103143A HK1148948A1 HK 1148948 A1 HK1148948 A1 HK 1148948A1 HK 11103143 A HK11103143 A HK 11103143A HK 1148948 A1 HK1148948 A1 HK 1148948A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- taci
- agents
- treatment
- combination
- autoimmune disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98033107P | 2007-10-16 | 2007-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1148948A1 true HK1148948A1 (zh) | 2011-09-23 |
Family
ID=40336534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11103143.7A HK1148948A1 (zh) | 2007-10-16 | 2011-03-29 | 用於治療自身免疫疾病的跨膜激活劑及鈣調親環素配基相互作用因子 和抗- 試劑的組合 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8956611B2 (zh) |
EP (2) | EP2233149B1 (zh) |
JP (2) | JP2011500715A (zh) |
AU (1) | AU2008312406B2 (zh) |
CA (1) | CA2701329C (zh) |
DK (1) | DK2233149T3 (zh) |
ES (1) | ES2565202T3 (zh) |
HK (1) | HK1148948A1 (zh) |
HU (1) | HUE030134T2 (zh) |
IL (1) | IL204849A (zh) |
PL (1) | PL2233149T3 (zh) |
WO (1) | WO2009052293A1 (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8809501B2 (en) * | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
TR201818978T4 (tr) * | 2011-11-04 | 2019-01-21 | Enceladus Pharmaceuticals B V | İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler |
US20130310546A1 (en) * | 2012-05-16 | 2013-11-21 | Bater Healthcare Sa | Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
AR104368A1 (es) * | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
CA3130132A1 (en) | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
JP2022539785A (ja) * | 2019-12-24 | 2022-09-13 | レメゲン シーオー.,エルティーディー. | TACI-Fc融合タンパク質及びその用途 |
AU2021268033A1 (en) | 2020-05-08 | 2022-12-15 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof |
WO2024023762A1 (en) * | 2022-07-27 | 2024-02-01 | Kashiv Biosciences, Llc | A stable liquid composition of ocrelizumab |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
GB8426467D0 (en) | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
US4657941A (en) | 1984-11-29 | 1987-04-14 | Dentsply Research & Development Corp. | Biologically compatible adhesive containing a phosphorus adhesion promoter and a sulfinic accelerator |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0397687B1 (en) | 1987-12-21 | 1994-05-11 | The University Of Toledo | Agrobacterium mediated transformation of germinating plant seeds |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
DK168302B1 (da) | 1989-06-29 | 1994-03-07 | Danisco | Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5716805A (en) | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5695760A (en) | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
US5853723A (en) | 1995-09-21 | 1998-12-29 | University Of Utah Research Foundation | Targeting of peg antibody conjugates to islet cells |
US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
WO1999002567A2 (en) | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
EA004107B1 (ru) | 1998-08-11 | 2003-12-25 | Айдек Фармацевтикалс Корпорэйшн | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
MY155913A (en) | 1998-11-09 | 2015-12-15 | Biogen Inc | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants |
WO2000027428A1 (en) | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1035172A3 (en) | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
DK1176981T3 (da) | 1999-05-07 | 2006-04-10 | Genentech Inc | Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer |
EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
DE19930748C2 (de) | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
IL147547A0 (en) | 1999-07-12 | 2002-08-14 | Genentech Inc | Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
CN101259270A (zh) | 1999-08-11 | 2008-09-10 | 拜奥根Idec公司 | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 |
DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
EP1254227A2 (en) | 2000-02-11 | 2002-11-06 | Amgen Inc. | Fusion receptor from tnf family |
DE60028830T2 (de) | 2000-02-16 | 2007-01-18 | Genentech, Inc., South San Francisco | Anti-april antikörper und hybridomazellen |
IL151906A0 (en) | 2000-03-24 | 2003-04-10 | Chiron Corp | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
CA2404365A1 (en) | 2000-03-31 | 2001-10-11 | Idec Pharmaceutical Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
KR20030016250A (ko) | 2000-04-25 | 2003-02-26 | 아이덱 파마슈티칼즈 코포레이션 | 중추신경계 림프종 치료용 리툭시맵의 초내 투여 |
AU2001253920B2 (en) | 2000-04-27 | 2006-03-16 | Apoxis Sa | Use of taci as an anti-tumor agent |
CA2408617A1 (en) | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
JP2004512262A (ja) | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | 非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ |
PT1296714E (pt) | 2000-06-22 | 2009-10-15 | Coley Pharm Gmbh | Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro |
SG136804A1 (en) | 2000-07-12 | 2007-11-29 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
WO2002034790A1 (en) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
ATE432986T1 (de) | 2000-11-07 | 2009-06-15 | Zymogenetics Inc | Menschlicher rezeptor für tumor necrosis factor |
CA2436092A1 (en) | 2001-01-29 | 2002-08-08 | Idec Pharmaceutical Corporation | Modified antibodies and methods of use |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
IL157946A0 (en) | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
EP1383800A4 (en) | 2001-04-02 | 2004-09-22 | Idec Pharma Corp | RECOMBINANT ANTIBODIES CO-EXPRESSED WITH GNTIII |
WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
KR20040030628A (ko) | 2001-05-24 | 2004-04-09 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
EP1404366A4 (en) | 2001-06-14 | 2006-06-07 | Intermune Inc | COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
PL377119A1 (pl) | 2001-08-03 | 2006-01-23 | Genentech, Inc. | Peptydy TACIs i BR3 i ich zastosowanie |
EP2131198B1 (en) | 2001-09-20 | 2013-03-27 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
US7151164B2 (en) | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
WO2003035846A2 (en) | 2001-10-24 | 2003-05-01 | National Jewish Medical And Research Center | Structure of tall-1 and its cognate receptor |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
CA2467521A1 (en) | 2001-11-16 | 2003-07-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to blys |
AU2002362098A1 (en) | 2001-12-07 | 2003-06-23 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
EP1629001A2 (en) * | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys antagonists and uses thereof |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
AU2006252733A1 (en) | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to CD20 and uses thereof |
US8784812B2 (en) | 2006-05-15 | 2014-07-22 | Zymogenetics, Inc. | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule |
PL2219675T3 (pl) | 2007-11-12 | 2014-04-30 | Ares Trading Sa | Formulacja dla białek fuzyjnych TACI-immunoglobulina |
JP5495607B2 (ja) * | 2008-05-27 | 2014-05-21 | キヤノン株式会社 | 超音波診断装置 |
JP5511201B2 (ja) * | 2008-07-31 | 2014-06-04 | キヤノン株式会社 | 信号処理装置、超音波装置、信号処理装置の制御方法及び超音波装置の制御方法 |
JP5483905B2 (ja) * | 2009-03-03 | 2014-05-07 | キヤノン株式会社 | 超音波装置 |
JP5393256B2 (ja) * | 2009-05-25 | 2014-01-22 | キヤノン株式会社 | 超音波装置 |
JP5725720B2 (ja) * | 2010-02-16 | 2015-05-27 | キヤノン株式会社 | 被検体情報処理装置 |
JP5424933B2 (ja) * | 2010-02-23 | 2014-02-26 | キヤノン株式会社 | 生体情報処理装置 |
JP5645421B2 (ja) * | 2010-02-23 | 2014-12-24 | キヤノン株式会社 | 超音波画像装置および遅延制御方法 |
-
2008
- 2008-10-16 DK DK10167232.7T patent/DK2233149T3/en active
- 2008-10-16 US US12/252,955 patent/US8956611B2/en active Active
- 2008-10-16 HU HUE10167232A patent/HUE030134T2/en unknown
- 2008-10-16 WO PCT/US2008/080177 patent/WO2009052293A1/en active Application Filing
- 2008-10-16 CA CA2701329A patent/CA2701329C/en active Active
- 2008-10-16 EP EP10167232.7A patent/EP2233149B1/en active Active
- 2008-10-16 PL PL10167232T patent/PL2233149T3/pl unknown
- 2008-10-16 EP EP08838758A patent/EP2200631A1/en not_active Withdrawn
- 2008-10-16 ES ES10167232.7T patent/ES2565202T3/es active Active
- 2008-10-16 JP JP2010530114A patent/JP2011500715A/ja not_active Withdrawn
- 2008-10-16 AU AU2008312406A patent/AU2008312406B2/en active Active
-
2010
- 2010-04-06 IL IL204849A patent/IL204849A/en active IP Right Grant
-
2011
- 2011-03-29 HK HK11103143.7A patent/HK1148948A1/zh unknown
-
2014
- 2014-07-03 JP JP2014137551A patent/JP5960756B2/ja active Active
-
2015
- 2015-01-12 US US14/594,457 patent/US20160051671A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2701329A1 (en) | 2009-04-23 |
EP2233149B1 (en) | 2016-02-10 |
US20090148442A1 (en) | 2009-06-11 |
PL2233149T3 (pl) | 2016-08-31 |
AU2008312406B2 (en) | 2014-03-06 |
JP5960756B2 (ja) | 2016-08-02 |
WO2009052293A1 (en) | 2009-04-23 |
IL204849A (en) | 2017-10-31 |
JP2014224120A (ja) | 2014-12-04 |
CA2701329C (en) | 2017-08-22 |
AU2008312406A1 (en) | 2009-04-23 |
JP2011500715A (ja) | 2011-01-06 |
ES2565202T3 (es) | 2016-04-01 |
EP2233149A1 (en) | 2010-09-29 |
US8956611B2 (en) | 2015-02-17 |
IL204849A0 (en) | 2010-11-30 |
US20160051671A1 (en) | 2016-02-25 |
HUE030134T2 (en) | 2017-04-28 |
DK2233149T3 (en) | 2016-05-17 |
EP2200631A1 (en) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1148948A1 (zh) | 用於治療自身免疫疾病的跨膜激活劑及鈣調親環素配基相互作用因子 和抗- 試劑的組合 | |
EP1890648A4 (en) | IMPLANTABLE MEDICINE PRODUCT WITH OPENINGS FOR DISTRIBUTING ADVANTAGEOUS MEDICINES WITH COMBINATION RELEASE KINETICS | |
EP2005806A4 (en) | SETTING PATIENTS BY TOMOSYNTHESIS TECHNIQUES | |
GB2455238B (en) | Patient monitor | |
EP2004809A4 (en) | EX VIVO CREATED TISSUE SYSTEM | |
EP2008572A4 (en) | CAPSULE MEDICAL DEVICE | |
ZA201101700B (en) | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment | |
EP1962722A4 (en) | METHOD AND SYSTEMS FOR TREATING ANEURYSMS USING FILLING STRUCTURES | |
PL2038268T3 (pl) | Karbonylowane (aza)cykloheksany jako ligandy receptora D3 dopaminy | |
EP2066460A4 (en) | COMBINED VIBRATOR SIEVE AND DEGREER | |
EP2233172A4 (en) | SYSTEM FOR STABILIZING BLOOD PRESSURE WITH TRANSDERMAL STIMULATION | |
EP2033569A4 (en) | CAPSULE MEDICAL DEVICE AND CAPSULE MEDICAL DEVICE SYSTEM | |
IL177683A0 (en) | Y2 selective receptor agonists for therapeutic interventions | |
GB0524428D0 (en) | Medicinal use of receptor ligands | |
EP2007453A4 (en) | SYRINGE BRAKE SYSTEM WITH SAFETY NEEDLE | |
IL195709A (en) | Form of administration of a solid drug that includes ethinyl estradiol | |
EP2021500A4 (en) | SELECTIVE MODULATION OF REGULATED RECEIVER SIGNALING | |
EP2196132A4 (en) | CAPSULE MEDICAL DEVICE AND MEDICAL SYSTEM | |
GB0416728D0 (en) | Medicinal use of receptor ligands | |
EP2083800A4 (en) | DEVICE AND METHOD FOR PATIENT-ACTIVATED BOLUS ADMINISTRATION | |
EP2056904A4 (en) | SYRINGE, CAPSULE DEVICE THEREFOR AND SPRAY DEVICE | |
TWI348495B (en) | Soil releasing agent containing fluoro-containing polymer | |
IL197332A0 (en) | Blood vessel prosthesis and delivery apparatus | |
EP1978082A4 (en) | bleach activator | |
GB0402796D0 (en) | An endoluminal surgical delivery system |